

IMMUNOGENETICS

Open Access

A novel splice variant of folate receptor 4 predominantly expressed in regulatory T cells

Yi Tian^{1†}, Guoqiang Wu^{2†}, Jun-Chao Xing^{2†}, Jun Tang³, Yi Zhang¹, Ze-Min Huang¹, Zheng-Cai Jia¹, Ren Zhao¹, Zhi-Qiang Tian¹, Shu-Feng Wang¹, Xiao-Ling Chen¹, Li Wang¹, Yu-Zhang Wu^{1*} and Bing Ni^{1*}

Abstract

Background: Regulatory T cells (Tregs) are required for proper maintenance of immunological self-tolerance and immune homeostasis. Folate receptor 4 (FR4) is expressed at high levels in transforming growth factor-beta (TGF- β)-induced Tregs and natural Tregs. Moreover, antibody-mediated targeting of FR4 is sufficient to mediate Treg depletion.

Results: In this study, we describe a novel FR4 transcript variant, FR4D3, in which exon 3 is deleted. The mRNA of FR4D3 encodes a FR4 variant truncated by 189 bp. FR4D3 was found to be predominantly expressed in CD4⁺CD25⁺ Treg cells. Overexpression of FR4D3 in CD4⁺CD25⁺ Treg cells *in vitro* stimulated proliferation, which may modulate the ability of these cells to bind and incorporate folic acid.

Conclusions: Our results suggested that high levels of FR4D3 may be critical to support the substantial proliferative capacity of Treg cells.

Keywords: Folate receptor 4, Variant, Regulatory T cells, Proliferation

Background

The folate receptor (FR), also known as the folic acid (FA) binding protein, is responsible for binding of 5-methyltetrahydrofolate (5-MeTHF) with high affinities (~100 pM Kd), thereby playing an important role in the uptake of serum folates by cells expressing this receptor [1,2]. Four isoforms of the human FR, FR- α , - β , - γ and - δ , have been identified and characterized. FR- α is predominantly expressed on epithelial cells [3,4]. FR- β is expressed only on activated macrophages and the surfaces of malignant cells of hematopoietic origin [5]. FR- γ was identified as a secretory protein from hematopoietic tissues, and demonstrated to have a much lower affinity for FA than FR- α [6,7]. FR- δ has proven difficult to detect in human tissues, suggesting a highly restricted spatial/temporal expression pattern, presence of a pseudogene, or predominance of an alternatively spliced variant [8]. Recent data, however, has indicated that FR- δ may be expressed on regulatory T cells (Tregs) [9].

Analysis of amino acid sequences in the mouse led to the identification of homologues of human FR- α and FR- β , known as folic acid-binding protein 1 and 2 (Folbp1/FR1 and Folbp2/FR2) [10]. Utilizing a 'genome database mining' strategy, Spiegelstein *et al.* identified a third murine FR, Folbp3 (also called FR4), which is highly homologous to human FR- δ [8,11]. In addition to regulating FA uptake, FR4 has been hypothesized to play a potential role in immune responses based upon its expression profile, which includes spleen- and thymus-related lymphoid tissues and lymphocytes [8]. Indeed, FR4 has been demonstrated to be exclusively expressed in splenic lymphocytes, especially in the T lymphocytes, and in mature thymocytes; however, few studies have reported on the characterization of FR4 [8,11].

Tregs are required for proper maintenance of immunological self-tolerance and immune homeostasis [12]. Studies to identify molecular markers of Tregs determined that FR4 is expressed at particularly high amounts in natural (n)Tregs and plays an important role in the maintenance of the Treg phenotype [13]. In our previous study, we identified a FR4 cDNA splice variant (FR4v) with intron 3 (108 bp) retained from the FR4 gene and confirmed protein expression of this variant

* Correspondence: wuyuzhang@yahoo.com; nibingxi@yahoo.com

†Equal contributors

¹Institute of Immunology, PLA, Third Military Medical University, Chongqing 400038, Peoples Republic of China

Full list of author information is available at the end of the article

[14]. Here, we report the identification of another FR4 transcript variant, named FR4D3, with the full-length exon 3 (189 bp) deleted. The FR4D3-encoded protein was confirmed to be expressed on CD4⁺CD25⁺ Tregs by Western blotting and fluorescence-activated cell sorting (FACS) assays. Finally, the role of the FR4D3 variant was investigated by overexpression in Treg cells *in vitro*.

Methods

Isolation of RNA, amplification and cloning of FR4D3

Six to eight-week-old female BALB/c mice were purchased from the Animal Center at the Chinese Academy of Medical Science (CAMS) branch in Beijing, China. All animals were maintained in pathogen-free conditions. All of the animal studies were approved by the Institutional Animal Care and Use Committee of the Third Military Medical University.

Total RNA was extracted from BALB/c mouse splenocytes using the TRIzol[®] reagent (Invitrogen, USA) according to the manufacturer's instructions. Approximately 1 µg of total RNA was reverse transcribed to cDNA using the High Fidelity PrimeScript[™] reverse transcription-polymerase chain reaction (RT-PCR) kit (TaKaRa, Japan). The cDNA was then used as template to PCR amplify the FR4 coding DNA sequence (CDS) with the following primers corresponding to the ends of exons 2 and 5 of the mouse FR4 gene, respectively: mFR4-F, 5'-ATGGCACAGTGGTGGCAGAT-3'; mFR4-R, 5'-TCAGG GATGGAACAACAGGC-3'. The PCR reaction was carried out under the following thermal cycling conditions: 30 cycles of 98°C for 10 s and 68°C for 40 s. The PCR amplicons were then subcloned into the pMD19-T vector (TaKaRa), and the clones were fully sequenced at Shanghai Sangon Biological Engineering Technology & Services Co., Ltd (China). The mRNA expression of FR4, FR4v and FR4D3 genes in splenocytes, CD4⁺ T cells, and CD4⁺CD25⁺ T cells were detected using RT-PCR assays with the following primers: 5'-GGGACAACTGCTCAGCGTCT-3' (forward) and 5'-AGACACCGCCCACTGTTTCT-3' (reverse).

To construct FR4- or FR4D3-expressing recombinant plasmids, the FR4 or FR4D3 coding sequence was PCR-amplified from BALB/c mouse splenocytes RNA and cloned directly into the pCI-neo vector (Promega, USA). The following primers were used: Forward primer: 5'-CCGCTCGAGGCCACCATGGCACAGTGGTGGCAGAT-3'; Reverse primer: 5'-CGTGGGTGCTCTAGATCAGGGATGGAACAACAGGC-3'.

FACS analysis

Approximately 1 × 10⁸ splenocytes were stained with anti-CD4-FITC, anti-CD25-PE and anti-CD8-PerCP-Cy5.5 antibodies (all from eBioscience, USA). The stained cells were separated by FACS into batches of

CD4⁺CD25⁺ T cells, CD4⁺CD25⁻ T cells, and CD8⁺ T cells with a FACS-Aria high-speed cell sorter (BD Biosciences, USA). The isolated CD4⁺CD25⁺ T cells were stained with intracellular anti-FOXP3-APC antibody (eBioscience, USA) and then detected by the FACS-Aria high-speed cell sorter.

Western blotting analysis

Isolated splenocytes and T cell subsets CD4⁺CD25⁻, CD4⁺CD25⁺, or CD8⁺ were lysed with the T-PER[®] Tissue Protein Extraction Reagent (Pierce, USA) at room temperature. After 5 min of lysis, the cell debris was removed *via* centrifugation at 12,000 rpm for 5 min at 4°C and the lysates were treated with N-glycosidase before blotting [15]. The protein-containing supernatant was mixed with 4 × nonreducing lithium dodecyl sulfate (LDS) sample buffer (Invitrogen) and heated for 10 min at 70°C. The protein samples (10–50 µg) were resolved by electrophoresis through NuPAGE[®] Novex 10% Bis-Tris mini-gels (Invitrogen) and transferred onto a polyvinylidene fluoride (PVDF) membrane (Millipore, Germany). After blocking of non-specific sites, the membranes were incubated with primary antibody (1:1,000 rat anti-mouse FR4; Abcam, United Kingdom) at 4°C overnight, followed by incubation with secondary antibody (1:10,000 goat anti-rat IgG; Abcam) for 1 h. Immunoreactive bands were observed using the enhanced chemiluminescence (ECL) detection reagents (Amersham Biosciences, United Kingdom), according to the manufacturer's instructions. β-actin was detected as an internal control (primary antibody: rabbit anti-mouse β-actin, secondary antibody: goat anti-rabbit IgG; both from Abcam).

The pCI-neo-FR4 or pCI-neo-FR4D3 vector (0.5 µg) was added to 2 × 10⁴ FACS-sorted CD4⁺CD25⁺ Tregs resuspended in 100 µL of mouse T cell Nucleofactor solution and electroporated using the 96-DN-100 program on the Nucleofactor instrument (Lonza, Germany). After 24 h of culture in serum-free conditions, the expressions of FR4 and FR4D3 proteins in the respective transfected cells were analyzed with Western blotting assay using anti-mouse FR4 (Abcam) as the primary antibody. The immunoreactive bands were scanned and densitometric analysis was performed by Bio-Rad Quantity One software.

Proliferation assays

The FACS-sorted CD4⁺CD25⁺ Tregs were stimulated with various concentrations of FA (0, 2, 4, 6, 8, 10 ng/mL; Sigma-Aldrich, USA) in the presence of interleukin (IL)-2 (300 U/mL; R&D Systems, USA), anti-CD3 (5 µg/mL; BD Biosciences)/anti-CD28 (2 µg/mL; BD Biosciences) (pre-coated and soluble, respectively). Cultures were incubated for three days and labeled with 0.5 µCi

(0.0185 MBq) [^3H]thymidine ([^3H]TdR; Hartmann Analytix, Germany) during the last 18 hours of incubation. [^3H]TdR incorporation was measured by a liquid scintillation counter (Top Count; Perkin Elmer, Germany). All assays were performed in triplicate.

The $\text{CD4}^+\text{CD25}^+$ Tregs transfected with pCI-neo-FR4 or pCI-neo-FR4D3 plasmids were seeded in 96-well U-bottom plates pre-coated with anti-CD3 (5 $\mu\text{g}/\text{mL}$) and co-stimulated for three days with soluble anti-CD28 (2 $\mu\text{g}/\text{mL}$), with or without IL-2 (300 U/mL) or FA (4, ng/mL). During the last 18 hours of culture, cells were labeled with 0.5 μCi (0.0185 MBq) [^3H]thymidine. [^3H]thymidine incorporation was measured by a liquid scintillation counter. All assays were performed in triplicate.

Statistical analysis

Relative comparisons of FR4 and FR4D3 proteins' intensity abundance between the transfected cells and untransfected cells detected by Western blot assay and the differences in proliferation of sorted $\text{CD4}^+\text{CD25}^+$ Tregs were analyzed by means of the 2-tailed Student's *t*-test. *P*-values less than 0.05 were considered significant.

Results

Identification of a novel FR4 isoform

When we amplified the full-length FR4 CDS from murine splenocytes by RT-PCR with the primer pair mFR4-F and mFR4-R (Figure 1A), three distinctive transcripts were amplified. The sizes of the two largest transcripts corresponded to the full-length FR4 (735 bp) and the variant FR4v (843 bp) [14]; however, the third transcript appeared to be a truncated form of FR4 (546 bp) (Figure 1B). The 546 bp PCR product was isolated, cloned and sequenced. Results showed that the 546 bp band's sequence was almost identical to the FR4 CDS, except with 189 bp of contiguous sequence deleted. Alignment analysis with FR4 mRNA sequence revealed that the missing 189 bp sequence corresponded to the entire exon 3 of the reported FR4 mRNA (Figure 1C). This newly identified splice variant of the FR4 gene was designated as FR4D3. Furthermore, the results indicated that the mature mRNAs of FR4D3, FR4v, and FR4 were generated from the same pro-mRNA. We then investigated the mRNA expression of FR4 gene variants in splenocytes, CD4^+ T cells, and $\text{CD4}^+\text{CD25}^+$ T cells, respectively. The RT-PCR assays revealed that all FR4 variants were expressed in these cell types, but the relative abundance of FR4D3 was lower than the other variants (Figure 1D).

Since the 189 bp-length exon 3 is composed of exactly 63 triplet codes of the FR4 mRNA, its elimination will not change the correct translation of FR4D3 mRNA. Therefore, Western blotting assay was used to determine

whether the FR4D3 protein was expressed in mouse spleen cells. As shown in Figure 1E, the anti-FR4 antibody detected both the full-length FR4 and the truncated FR4D3 variant in mouse splenocytes, whose predicted molecular masses were approximately 28 kDa and 21 kDa, respectively. The sequence and theoretical translation of this novel cDNA were submitted to GenBank and can be found under accession numbers EU326439.1 and ABY56299.1, respectively.

Predominant expression of FR4D3 in $\text{CD4}^+\text{CD25}^+$ regulatory T cells

It has been reported that natural Treg cells constitutively express higher amounts of FR4 [13]. In order to examine whether the FR4D3 exhibits a differential distribution in T cell subpopulations, high purity populations of specific T cell subtypes were obtained by FACS sorting. The purity of isolated CD8^+ , $\text{CD4}^+\text{CD25}^-$, and $\text{CD4}^+\text{CD25}^+$ T cells reached 99.3%, 99.0%, and 98.3%, respectively (Figure 2A). After sorting, we detected the purity of Foxp3-positive cells in the isolated $\text{CD4}^+\text{CD25}^+$ T cells and found that the Foxp3-positive cells reached ~91%, suggesting that most of the isolated $\text{CD4}^+\text{CD25}^+$ T cells were Tregs (Figure 2B). Western blotting analysis of these subtypes showed that FR4 and FR4D3 proteins were expressed in $\text{CD4}^+\text{CD25}^+$ Tregs at a higher level than in either $\text{CD4}^+\text{CD25}^-$ or CD8^+ T cells (Figure 2C). These results suggested that FR4D3 may play a redundant or unique functional role in $\text{CD4}^+\text{CD25}^+$ Tregs.

Effect of overexpression of FR4D3 on proliferation of $\text{CD4}^+\text{CD25}^+$ T cells

The capacity to efficiently bind and incorporate folic acid is linked to cellular proliferation, and indeed overexpression of folate receptors is a characteristic feature of certain tumors [16]. It has been reported that FR4 is not merely a marker of natural Treg cells but is also functionally essential for their maintenance since blockade of FR4 was sufficient to reduce natural Treg cells *in vivo* [13]. In order to investigate the function of FR4 and FR4D3, we respectively overexpressed each in the isolated $\text{CD4}^+\text{CD25}^+$ Tregs. Results showed that the level of FR4 or FR4D3 protein was much higher in transfected cells than in untransfected cells (Figure 3A). We then examined the proliferative ability of FACS-sorted $\text{CD4}^+\text{CD25}^+$ Tregs in response to stimulation with FA, in the presence of IL-2, anti-CD3/anti-CD28 (pre-coated and soluble, respectively) *in vitro*. Results should that only simultaneous stimulation with anti-CD3/anti-CD28 in the presence of IL-2 could abrogate the anergic state of $\text{CD4}^+\text{CD25}^+$ Tregs. Moreover, the proliferative ability of these cells was further enhanced by addition of FA to the stimulation mixture in a dose-response manner (Figure 3B), and FA mediated more proliferation than




Figure 1 Identification of a novel truncated FR4 variant from BALB/c mouse splenocytes. (A) Schematic diagram of the mouse FR4 gene. Exons are indicated by solid lines, and introns by dashed lines. Positions of primers used for PCR amplification are shown by arrows. (B) RT-PCR detection of full-length CDS of FR4 and FR4D3 genes in mouse splenocytes. (C) RT-PCR detection of FR4 and FR4D3 mRNA in splenocytes, CD4⁺ T cells, and CD4⁺CD25⁺ T cells. (D) The nucleotide and predicted amino acid sequences of the novel mouse FR4D3 CDS. The 189 bp exon 3 was deleted and did not cause frame shift mutation. The exons are indicated in bold and the exon-exon junction sites are indicated by arrows. (E) Western blotting assay showing FR4 and FR4D3 proteins detected by rat anti-mouse FR4 monoclonal antibody (mAb). Here, 50 μg splenocyte lysates were treated with N-glycosidase before blotting [15].

simply overexpressing the FR4D3 gene (Figure 3C). However, the proliferation capacity of cells induced with FA + IL-2 + anti-CD3/anti-CD28 was even further enhanced by overexpression of FR4 or FR4D3 (Figure 3C), indicating that both receptors have a substantial capacity to uptake the FA substrate. The wild-type (Wt) FR4 appeared to have stronger ability to uptake FA than the

FR3D3 variant since overexpression of the former showed higher proliferative capacity in the presence of the FA substrate (Figure 3C).

Discussion

In this study, we have identified a novel alternative splicing variant of the FR4 gene, named FR4D3, which lacks




Figure 2 Expression of the novel FR4D3 variant in splenic T cell sub populations. (A) Isolation and purity (%) of splenic T cell subpopulations. (B) Purity of Foxp3-positive cells in isolated CD4⁺CD25⁺ T cells. (C) FR4D3 protein expression in particular T cell subsets was detected by Western blotting assay using anti-mouse FR4 mAb. Here, 10 μg of total cell extracts was treated with N-glycosidase before blotting. β-actin protein was detected as an internal control.

the entire exon 3 of the FR4 gene. FR4D3 proteins were found to be expressed in CD4⁺CD25⁺ Tregs at a higher level than in CD4⁺CD25⁻ or CD8⁺ T cells. Furthermore, overexpression of FR4D3 in FACS-sorted CD4⁺CD25⁺ Tregs was found to enhance proliferative capacity of these cells *in vitro*.

Recent studies have demonstrated that nearly every multi-exon gene, including “constitutively” spliced genes [17], produces alternative mRNA isoforms [18]. Although many of these isoforms have important

functional roles, it is clear that some of these mRNAs are produced by errors that occur during the splicing process [19]. In fact, different RNA quality controls have evolved to recognize and degrade such errors. For those mRNAs that escape detection and destruction, expression may be at such low levels that the new mRNA isoforms may be tolerated by the cell, eventually representing an evolutionary precursor [20,21].

Previous studies have suggested that FR4 is exclusively expressed by splenic lymphocytes, especially the T




Figure 3 Proliferation of sorted CD4⁺CD25⁺ Tregs. (A) Overexpression of FR4 or FR4D3 protein in sorted CD4⁺CD25⁺ Tregs. Wt, wild type cells; Over-FR4, overexpression of FR4; Over-FR4D3, overexpression of FR4D3. Each column represents the intensity abundance ratio of the FR4 or FR4D3 band versus the actin band in each lane. Panels show a representative of three independent experiments. Error bars represent the standard deviation from three independent experiments. *, $P < 0.05$, vs. wild type cells. (B) FA dose-response of Tregs' proliferation. The CD4⁺CD25⁺ Tregs were stimulated with various concentrations of FA (0, 2, 4, 6, 8, 10 ng/mL) in the presence of IL-2, anti-CD3/anti-CD28 (pre-coated and soluble, respectively). Panels show a representative of three independent experiments. Error bars represent the standard deviation from triplicate wells. *, $P < 0.05$ vs. untreated cells. (C) The FR4 or FR4D3 CDS was cloned directly into the pCI-neo vector and transiently transfected into FACS-sorted CD4⁺CD25⁺ Tregs, followed by stimulation with or without combinations of FA, IL-2, and anti-CD3/anti-CD28 (pre-coated and soluble, respectively). Wt represents no overexpression of either FR4 or FR4D3; FR4 represents the overexpression of FR4; FR4D3 represents the overexpression of FR4D3. Panels show a representative of three independent experiments. Error bars represent the standard deviation from triplicate wells. *, $P < 0.05$.

lymphocytes, and mature thymocytes. Subsequent study identified particularly high expression in the nTregs T cell subpopulation [13]. In our current study, we found that *FR4D3* was expressed in $CD4^+CD25^+$ Tregs at a higher level than in either $CD4^+CD25^-$ or $CD8^+$ T cells, suggesting that the expression of *FR4D3* was cell type-specific. Retroviral transduction of *Foxp3*, which can functionally and phenotypically convert normal T cells to natural Treg-like cells [22,23], has revealed that the *FR4* expression was proportional to that of *Foxp3* in *Foxp3*-transduced $CD25^+CD4^+$ T cells, suggesting that *Foxp3* can control, either directly or indirectly, the expression of *FR4* in natural Treg cells [13]. Further research is necessary to determine whether transduction with *Foxp3* is also sufficient to mediate *FR4D3* up-regulation.

As previously described for $CD4^+CD25^+$ Tregs, the anergic state of a pure $CD4^+CD25^+$ Treg subpopulation is abrogated after simultaneous stimulation of T cell receptors (TCRs) and *CD28* in the presence of *IL-2*; neither *IL-2* nor plate-bound anti-*CD3* combined with soluble anti-*CD28* could resolve the cells' unresponsiveness [24,25]. Furthermore, the capacity to efficiently bind and incorporate folic acid is linked to cellular proliferation, in both normal and tumorigenic conditions. In our current study, we found that overexpressing *FR4D3* or *FR4* in $CD4^+CD25^+$ Tregs could further enhance the proliferation induced by *FA*, *IL-2*, and anti-*CD3*/anti-*CD28* (pre-coated and soluble, respectively) *in vitro*. These results suggested that high expression of *FR4D3* could facilitate binding of *FA* and cellular uptake, which may be critical to support the substantial proliferative capacity of Tregs *in vivo*. Of course, the *FR4D3* may have other yet unrecognized functions, which will require further investigation. We also found that the *FA* + *IL-2* + anti-*CD3*/anti-*CD28* induced proliferative capacity of $CD4^+CD25^+$ Tregs overexpressing *FR4D3* was weaker than in $CD4^+CD25^+$ Tregs overexpressing *FR4*. These results suggested that the exon 3-related sequences contribute to optimal *FA* binding and/or cellular uptake mediated by *FR4*.

Conclusions

In conclusion, we have identified a novel exon 3-deleted *FR4* transcript variant, which encodes a 189 bp truncated protein that is predominantly expressed in $CD4^+CD25^+$ Treg cells. The high expression of *FR4D3* in $CD4^+CD25^+$ Tregs may modulate the ability of these cells to bind and incorporate folic acid, possibly in normal or pathogenic conditions that would benefit from enhanced proliferation of these cells.

Competing interests

The authors have declared that no competing interests exist.

Acknowledgements

This work was supported by grants from the General Program of National Natural Science Foundation of China (Nos. 31070798 and 30901337) and the Key Program of the National Natural Science Foundation of China (30930086).

Author details

¹Institute of Immunology, PLA, Third Military Medical University, Chongqing 400038, Peoples Republic of China. ²Department of general surgery, the general hospital of ShenYang military area command, ShenYang 110016, Peoples Republic of China. ³Department of Dermatology, the 105th Hospital of PLA, Hefei 230001, Peoples Republic of China.

Authors' contributions

Yi Tian, Guoqiang Wu and Jun-Chao Xing carried out the isolation of RNA, amplification and cloning of *FR4D3*. Jun Tang and Yi Zhang carried out the FACS assay. Ze-Min Huang and Zheng-Cai Jia carried out the Western blotting analysis. Ren Zhao, Zhi-Qiang Tian and Li Wang carried out the proliferation assays. Xiao-Ling Chen and Shu-Feng Wang carried out the Statistical analysis. Yuzhang Wu and Bing Ni conceived the study, and participated in its design and coordination and drafted the manuscript equally. All authors read and approved the final manuscript.

Received: 23 March 2012 Accepted: 13 June 2012

Published: 13 June 2012

References

1. Shen F, Ross JF, Wang X, Ratnam M: Identification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity. *Biochemistry* 1994, **33**(5):1209–1215.
2. Antony AC: Folate receptors. *Annu Rev Nutr* 1996, **16**:501–521.
3. Weitman SD, Weinberg AG, Coney LR, Zurawski VR, Jennings DS, Kamen BA: Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. *Cancer Res* 1992, **52**(23):6708–6711.
4. Kamen BA, Smith AK: A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models *in vitro*. *Adv Drug Deliv Rev* 2004, **56**(8):1085–1097.
5. Xia W, Hilgenbrink AR, Matteson EL, Lockwood MB, Cheng JX, Low PS: A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. *Blood* 2009, **113**(2):438–446.
6. Shen F, Wu M, Ross JF, Miller D, Ratnam M: Folate receptor type gamma is primarily a secretory protein due to lack of an efficient signal for glycosylphosphatidylinositol modification: protein characterization and cell type specificity. *Biochemistry* 1995, **34**(16):5660–5665.
7. Blom HJ: Folic acid, methylation and neural tube closure in humans. *Birth Defects Res A Clin Mol Teratol* 2009, **85**(4):295–302.
8. Spiegelstein O, Eudy JD, Finnell RH: Identification of two putative novel folate receptor genes in humans and mouse. *Gene* 2000, **258**(1–2):117–125.
9. Low PS, Kularatne SA: Folate-targeted therapeutic and imaging agents for cancer. *Curr Opin Chem Biol* 2009, **13**(3):256–262.
10. Barber RC, Bennett GD, Greer KA, Finnell RH: Expression patterns of folate binding proteins one and two in the developing mouse embryo. *Mol Genet Metab* 1999, **66**(1):31–39.
11. Elnakat H, Ratnam M: Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. *Adv Drug Deliv Rev* 2004, **56**(8):1067–1084.
12. Vignali DA, Collison LW, Workman CJ: How regulatory T cells work. *Nat Rev Immunol* 2008, **8**(7):523–532.
13. Yamaguchi T, Hirota K, Nagahama K, Ohkawa K, Takahashi T, Nomura T, Sakaguchi S: Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. *Immunity* 2007, **27**(1):145–159.
14. Jia Z, Zhao R, Tian Y, Huang Z, Tian Z, Shen Z, Wang Q, Wang J, Fu X, Wu Y: A novel splice variant of *FR4* predominantly expressed in $CD4^+CD25^+$ regulatory T cells. *Immunol Invest* 2009, **38**(8):718–729.
15. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S: Stimulation of $CD25^+(+)CD4^+(+)$ regulatory T cells through *GITR* breaks immunological self-tolerance. *Nat Immunol* 2002, **3**(2):135–142.
16. Segal EI, Low PS: Tumor detection using folate receptor-targeted imaging agents. *Cancer Metastasis Rev* 2008, **27**(4):655–664.

17. Fox-Walsh KL, Hertel KJ: **Splice-site pairing is an intrinsically high fidelity process.** *Proc Natl Acad Sci USA* 2009, **106**(6):1766–1771.
18. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ: **Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing.** *Nat Genet* 2008, **40**(12):1413–1415.
19. Hsu SN, Hertel KJ: **Spliceosomes walk the line: splicing errors and their impact on cellular function.** *RNA Biol* 2009, **6**(5):526–530.
20. Sestili P, Barbieri E, Martinelli C, Battistelli M, Guescini M, Vallorani L, Casadei L, D'Emilio A, Falcieri E, Piccoli G, *et al*: **Creatine supplementation prevents the inhibition of myogenic differentiation in oxidatively injured C2C12 murine myoblasts.** *Mol Nutr Food Res* 2009, **53**(9):1187–1204.
21. Annibalini G, Guescini M, Agostini D, Matteis RD, Sestili P, Tibollo P, Mantuano M, Martinelli C, Stocchi V: **The expression analysis of mouse interleukin-6 splice variants argued against their biological relevance.** *BMB Rep* 2012, **45**(1):32–37.
22. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY: **A function for interleukin 2 in Foxp3-expressing regulatory T cells.** *Nat Immunol* 2005, **6**(11):1142–1151.
23. Hori S, Nomura T, Sakaguchi S: **Control of regulatory T cell development by the transcription factor Foxp3.** *Science* 2003, **299**(5609):1057–1061.
24. Hoffmann P, Eder R, Kunz-Schughart LA, Andreesen R, Edinger M: **Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells.** *Blood* 2004, **104**(3):895–903.
25. Fantini MC, Dominitzki S, Rizzo A, Neurath MF, Becker C: **In vitro generation of CD4+ CD25+ regulatory cells from murine naive T cells.** *Nat Protoc* 2007, **2**(7):1789–1794.

doi:10.1186/1471-2172-13-30

Cite this article as: Tian *et al.*: A novel splice variant of folate receptor 4 predominantly expressed in regulatory T cells. *BMC Immunology* 2012 **13**:30.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

